Recommended starting dose once daily
39.2 mg/In a clinical study of patients with ADHD aged 6 to 12 years, most patients were optimized on higher doses2,a
were optimized to
26.1 mg/5.2 mg
were optimized to
39.2 mg/7.8 mg
were optimized to
52.3 mg/10.4 mg
aThe randomized, double-blind, placebo-controlled, parallel-group, analog classroom study included pediatric patients with
ADHD aged 6 to 12 years (mean, 9.6 years). During the open-label dose-optimization phase (3 weeks), 155 patients were started
on AZSTARYS 39.2 mg/7.8 mg once daily in the morning. The dose could be titrated weekly to 26.1 mg/5.2 mg, 39.2 mg/7.8 mg,
or 52.3 mg/10.4 mg (maximum dose) based on tolerability and best individual response in the opinion of the investigator.1,2
bThe percentage of patients optimized does not add to 100% because 5 patients dropped out of the dose-optimization phase
(4 due to AEs and 1 failed to meet randomization criteria). The percentages here are calculated based on a total population of 55 patients.1,2
SDX
IR d-MPH
AZSTARYS (SDX/d-MPH) |
Combined molar dose over the day (d-MPH HCl) |
---|---|
26.1 mg/5.2 mg | 20 mg |
39.2 mg/7.8 mg | 30 mg |
52.3 mg/10.4 mg | 40 mg |
AE, adverse events; d-MPH, dexmethylphenidate; HCL, hydrochloride; IR, immediate-release; MPH, methylphenidate; PK, pharmacokinetic; SDX, serdexmethylphenidate.
References: 1. AZSTARYS. Prescribing information.
Corium Inc; 2021.
2. Data on file. Corium, Inc.
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder
(ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE
Please click here for Full
Prescribing Information,
including Boxed WARNING.
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE